BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
77.19
+2.67 (3.58%)
At close: Jul 2, 2026, 4:00 PM EDT
77.10
-0.09 (-0.12%)
After-hours: Jul 2, 2026, 7:07 PM EDT
BridgeBio Pharma Revenue
BridgeBio Pharma had revenue of $194.52M in the quarter ending March 31, 2026, with 66.78% growth. This brings the company's revenue in the last twelve months to $579.96M, up 355.17% year-over-year. In the year 2025, BridgeBio Pharma had annual revenue of $502.08M with 126.26% growth.
Revenue (ttm)
$579.96M
Revenue Growth
+355.17%
P/S Ratio
26.07
Revenue / Employee
$691,249
Employees
839
Market Cap
15.12B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 502.08M | 280.17M | 126.26% |
| Dec 31, 2024 | 221.90M | 212.60M | 2,285.27% |
| Dec 31, 2023 | 9.30M | -68.35M | -88.02% |
| Dec 31, 2022 | 77.65M | 7.93M | 11.38% |
| Dec 31, 2021 | 69.72M | 61.47M | 745.14% |
| Dec 31, 2020 | 8.25M | -32.31M | -79.66% |
| Dec 31, 2019 | 40.56M | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jazz Pharmaceuticals | 4.44B |
| Genmab | 3.90B |
| BioMarin Pharmaceutical | 3.24B |
| Exelixis | 2.38B |
| Madrigal Pharmaceuticals | 1.13B |
| Ionis Pharmaceuticals | 1.06B |
| Ascendis Pharma | 998.25M |
| Axsome Therapeutics | 708.24M |
BBIO News
- 19 hours ago - Acoramidis Associated with First-Ever Early and Sustained Direct Kidney-Protective Effects in ATTR-CM - GlobeNewsWire
- 1 day ago - BridgeBio Raises $1 Billion in Preferred Equity to Accelerate Present and Upcoming Launches - GlobeNewsWire
- 4 days ago - BridgeBio announces PROPEL 3 trial met primary endpoint - TheFly
- 4 days ago - BridgeBio Announces Publication in the New England Journal of Medicine of Phase 3 PROPEL 3 Trial of Oral Infigratinib in Children Living with Achondroplasia - GlobeNewsWire
- 4 days ago - BridgeBio Pharma Slides: Conference presentation - Filings
- 9 days ago - BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 10 days ago - BridgeBio Pharma Transcript: AGM 2026 - Transcripts
- 10 days ago - BridgeBio to Present Primary Results from Phase 3 PROPEL 3 Trial of Oral Infigratinib for Children Living with Achondroplasia at ICCBH 2026 - GlobeNewsWire